The past year in the field of cellular immunotherapy in hematological malignancies has been extremely exciting. We saw FDA approval of the first CAR-T therapy for patients with ALL and then additional approvals for certain types of lymphoma. With several cellular immunotherapy products in development, it is indeed a thrilling time to be involved in the clinical trials of these novel therapies. At the annual American Society of Hematology conference this year, I am looking forward to learning more of recent advances, successes and challenges in developing these therapeutics as we all work together to overcome these hematological diseases that affect so many.
Cmed to Demonstrate encapsia at Two Leading Oncology Meetings
13 Nov 2017
Cloud-based Clinical Data Suite to be Showcased at Clinical Operations in Oncology Trials Europe and the ASH Annual Meeting Cmed, an oncology focused, innovative technology-led CRO, today announced that it will showcase its encapsia® clinical data suite at two leading oncology meetings, Clinical Operations in Oncology Trials Europe, taking place 5-6 December in Munich, Germany, and the ASH Annual Meeting, taking place 9-12 December in Atlanta, GA.
As a full-service CRO, Cmed has a strong reputation in delivering complex and demanding clinical trials across numerous oncology types, including various haematological indications, immuno-oncology, breast, lung, prostate and colorectal.
Cmed to Showcase Advanced Data Insights and Analytics Capabilities of encapsia® Clinical Data Suite at Partnerships in Clinical Trials Europe Cmed, an innovative technology-led CRO, will demonstrate its encapsia® clinical data suite at Partnerships in Clinical Trials Europe, taking place 28-29 November 2017 in Amsterdam, The Netherlands. Currently used in trials with nine Pharma companies, including two of the top five, for a variety of electronic data capture (EDC) and direct data capture eSource clinical trials, the solution provides sponsors and their partners with a single point of access for live views of data at any point in a clinical trial.
The promise of EDC to improve the speed and quality of clinical trials was never really fulfilled. In reality, nothing has fundamentally changed in how clinical trials are conducted. With new hardware, we can begin utilizing tablets such as iPads to directly capture data at site.
Can you imagine the transformation from traditional EDC data collection into eSource with an iPad? eSource is available NOW as part of Cmed’s encapsia® clinical data suite - why wait?